Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

Anthony R. Mato(Memorial Sloan Kettering Cancer Center), John C. Byrd(University of Cincinnati), Richard R. Furman(Cornell University), Lang Zhou(Qingdao University), Steven Coutré(Georgetown University), Paul M. Barr(University of Rochester Medical Center), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Herbert Eradat(University of Colorado Cancer Center), Michael Y. Choi(University of California San Diego), Bruce D. Cheson(Center for Cancer and Blood Disorders), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Leonard T. Heffner, Maria Verdugo(AbbVie (United States)), Sharanya Ford(AbbVie (United States))
Haematologica
March 28, 2019
10.3324/haematol.2018.207068
Cited by 40

Related Papers

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k